CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Relapsed and chemotherapy-refractory B-cell acute lymphoblastic leukemia (B-ALL) remain significant causes of cancer-associated morbidity and mortality for children and adults. Development of new molecularly targeted treatment strategies for patients with high-risk B-ALL is thus a major preclinical and clinical priority. Adoptive cellular therapy with patient-derived human T cells genetically engineered to express CD19 redirected chimeric antigen receptors (CD19 CAR T cells) is one immunotherapeutic modality that has recently demonstrated remarkable efficacy in re-inducing remission in patients with multiply relapsed B-ALL. Investigative teams at several major cancer centers are currently conducting phase I clinical trials in children and/or adults with relapsed/refractory B-ALL to assess the safety and to identify the maximally tolerated dose of each group’s CD19 CAR T-cell product. All groups have reported major clinical toxicities associated with CD19 CAR T-cell treatment, including cytokine release syndrome (CRS) and macrophage activation syndrome, neurologic dysfunction and aplasia of normal B lymphocytes, while CD19 CAR T cells persist in vivo. Toxicities have generally been transient or manageable with supportive care measures. Some patients with life-threatening CD19 CAR T-cell induced sequelae have received anti-cytokine receptor antibody treatment to diminish CRS symptoms and/or corticosteroids to terminate CAR T-cell proliferation. Remarkably, 67–90% of children and adults with B-ALL treated with CD19 CAR T cells in these trials have achieved morphologic leukemia remission with many patients also in molecular remission. The duration of CD19 CAR T cell persistence in vivo has varied appreciably among treated patients and likely reflects differences in the CD19 CAR constructs utilized at each institution. CD19-positive and CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients. Phase II trials to assess the efficacy of CD19 CAR T-cell immunotherapy in larger cohorts of patients with relapsed/refractory B-ALL are ongoing or planned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 14×
“…as a possible biomarker of CRS, some institutions have also treated patients with severe CRS with tocilizumab in an effort to dampen the immune activation and associated sequelae without terminating CAR T cells with lymphotoxic steroids [Barrett et al. 2014; Lee et al. 2014a; Maude et al. 2014a].”
BackgroundMethodInfluentialChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 5×
“…(CHOP/Penn) recently published updated results of their phase I trials of lentivirally-transduced CD19 CAR T cells with CD3ζ and 4-1BB (CD137) endodomains (CD19CAR-CD3ζ-41BB) in 30 children and adults with relapsed/refractory B-cell malignancies [Grupp et al. 2013; Grupp, 2014; Maude et al. 2014b].”
BackgroundMethodInfluentialLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · cited 1×
“…patients with severe cytomegalovirus, Epstein– Barr virus and adenovirus infections after HSCT with engineered trivirus-specific T cells (VSTs) [Leen et al. 2006; Micklethwaite et al. 2010], the BCM team subsequently hypothesized that CD19-redirected VSTs (CD19.CAR-VSTs) could be activated…”
BackgroundCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 10×
“…as a possible biomarker of CRS, some institutions have also treated patients with severe CRS with tocilizumab in an effort to dampen the immune activation and associated sequelae without terminating CAR T cells with lymphotoxic steroids [Barrett et al. 2014; Lee et al. 2014a; Maude et al. 2014a].”
BackgroundMethodInfluentialSelf-citationBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 1×
“…NCT01044069] Investigators at the Memorial Sloan Kettering Cancer Center (MSKCC) have published data from several phase I trials testing CD19 CAR T cells in adults with relapsed/refractory B-cell malignancies, including B-ALL, CLL and other NHL [Brentjens et al. 2011, 2013; Davila et al. 2014].”
BackgroundAdoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · cited 1×
“Various immunotherapeutic modalities and strategies in development for solid tumors and hematologic malignancies have been described comprehensively in other reviews [Park et al. 2011; Restifo et al. 2012; Fry and Mackall, 2013; Sadelain et al. 2013; Mantripragada et al. 2014].”
BackgroundPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269 · cited 1×
“The CHOP/Penn investigators specifically noted an 82% CR rate in children and adults with high levels of disease burden (i.e. >50% leukemia marrow involvement), a population of patients in whom blinatumomab may have diminished efficacy [Topp et al. 2014, 2015].”
BackgroundMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“…231 line-xenografted mice with retrovirus- or lentivirus-transduced CD19 CAR T cells (second generation) resulted in systemic trafficking of T cells to sites of CD19+ disease and in successful eradication of leukemia [Brentjens et al. 2007; Milone et al. 2009; Barrett et al. 2011].”
BackgroundInaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074 · cited 3×
“com 229 chemotherapy is highly predictive of future ALL relapse, which occurs in 15–20% of children with ALL and remains a leading cause of pediatric cancer mortality [Nguyen et al. 2008; Bhojwani and Pui, 2013; Inaba et al. 2013].”
Background
Cited by
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
“The endodomain is the functional end of the receptor, and the most common component is CD3 ζ included three immunoreceptor tyrosine-based activation motifs (ITAMs) [3, 4].”
Pluripotent stem cells progressing to the clinic
Trounson, A., & DeWitt, N. D. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.10 · Cited by 379
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Self-citationBuilding a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M.-A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.10.017 · Cited by 59
“CD19-specific Chimeric Antigen Receptor (CAR) T-cell immunotherapy has shown significant antitumor activity in the treatment of high-risk relapsed and refractory leukemias and lymphomas, and has revolutionized the treatment landscape for patients with advanced lymphoid malignancies [1-19].”
Fu, R. Y., Chen, A. C., Lyle, M. J., Chen, C.-Y., Liu, C. L., & Miao, C. H. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104216 · Cited by 34
Metadata
- Authors
- Tasian, S. K., & Gardner, R. A.
- Venue
- Therapeutic Advances in Hematology
- Publisher
- SAGE Publications
- Published
- 2015-07-06
- Volume
- 6
- Issue
- 5
- Pages
- 228-241
- ISSN
- 2040-6207 (ISSN-L)
- 2040-6215
- OpenAlex
- W2157258473
- Cited by
- 117
- References
- 12
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). https://app.cochat.ai/papers/10.1177/2040620715588916
- The paper
- Tasian, S. K., & Gardner, R. A. (2015). CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Therapeutic Advances in Hematology. https://doi.org/10.1177/2040620715588916
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.